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Abstract
Survival of Pseudomonas aeruginosa in cystic fibrosis (CF) chronic infections is based on a genetic adaptation process
consisting of mutations in specific genes, which can produce advantageous phenotypic switches and ensure its persistence
in the lung. Among these, mutations inactivating the regulators MucA (alginate biosynthesis), LasR (quorum sensing) and
MexZ (multidrug-efflux pump MexXY) are the most frequently observed, with those inactivating the DNA mismatch repair
system (MRS) being also highly prevalent in P. aeruginosa CF isolates, leading to hypermutator phenotypes that could
contribute to this adaptive mutagenesis by virtue of an increased mutation rate. Here, we characterized the mutations
found in the mucA, lasR, mexZ and MRS genes in P. aeruginosa isolates obtained from Argentinean CF patients, and analyzed
the potential association of mucA, lasR and mexZ mutagenesis with MRS-deficiency and antibiotic resistance. Thus, 38
isolates from 26 chronically infected CF patients were characterized for their phenotypic traits, PFGE genotypic patterns,
mutations in the mucA, lasR, mexZ, mutS and mutL gene coding sequences and antibiotic resistance profiles. The most
frequently mutated gene was mexZ (79%), followed by mucA (63%) and lasR (39%) as well as a high prevalence (42%) of
hypermutators being observed due to loss-of-function mutations in mutL (60%) followed by mutS (40%). Interestingly,
mutational spectra were particular to each gene, suggesting that several mechanisms are responsible for mutations during
chronic infection. However, no link could be established between hypermutability and mutagenesis in mucA, lasR and mexZ,
indicating that MRS-deficiency was not involved in the acquisition of these mutations. Finally, although inactivation of
mucA, lasR and mexZ has been previously shown to confer resistance/tolerance to antibiotics, only mutations in MRS genes
could be related to an antibiotic resistance increase. These results help to unravel the mutational dynamics that lead to the
adaptation of P. aeruginosa to the CF lung.
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Introduction
The opportunistic pathogen Pseudomonas aeruginosa is the leading
cause of morbidity and mortality in CF patients, producing
chronic pulmonary infections that can persist over decades [1,2].
After a period of recurrent infections, CF patients become infected
permanently by a single lineage of P. aeruginosa, generally acquired
from environmental reservoirs [3]. During the establishment of the
infection, this single P. aeruginosa lineage diversifies into phenotypes
specifically adapted to the hostile environment of the CF lung, thus
allowing its long-term persistence [4]. These phenotypes possess
traits that differ from environmental isolates, but which are
commonly observed among CF patients, suggesting a conserved
evolutionary pattern in the adaptive process of P. aeruginosa to the
CF lung [5,6]. Well-known examples of this diversification process
include conversion to the mucoid phenotype [1,7], loss of the O
antigen [8], inactivation of quorum sensing functions [6,9,10], loss
of motility [11,12], auxotrophies [13], resistance to antibiotics
[14], and a rise in the mutation rate leading to a hypermutator
phenotype.
The acquisition of these P. aeruginosa CF adaptive phenotypes is
mainly based on the occurrence (and further selection) of loss-of-
function mutations in specific genes. Among these, the most
commonly mutated is mucA, which encodes for a negative
regulator of the biosynthesis of the exopolysaccharide alginate
and whose inactivation is the basis of the conversion to the mucoid
phenotype [7]. Another gene, commonly altered even at the early
stages of P. aeruginosa CF infections, is lasR, which is the main
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virulence traits [6,9,10]. Moreover, genes which regulate the
expression of multidrug-efflux pumps are frequently mutated, such
as mexZ, a negative regulator of the MexXY-OprM multidrug-
efflux pump, whose inactivation increases the resistance to
aminoglycoside and other drugs [6,15].
Another highly prevalent phenotype observed in P. aeruginosa
isolates from CF patients is the hypermutator phenotype [16–19],
with hypermutator strains displaying high mutation rates, mainly
due to alterations in the genes of the DNA mismatch repair system
(MRS) [20]. This phenotype has been reported in CF patients
from both Europe and North America [16,19,21–24], suggesting
that this could be a worldwide phenomenon. Moreover, this high
prevalence of hypermutators seems to be essentially associated to
chronic infections, since it has only very occasionally been
observed in either acute infections or environmental samples
(#1%) [19,24], indicating that it could be linked with the
particular genetic adaptive process taking place during the
establishment and persistence of P. aeruginosa infections. In fact,
the link between the acquisition of antimicrobial resistance and
hypermutators has been well-established by in vitro and in vivo
approaches [16,17,19,25–28]. However, antibiotic resistance is not
only a phenomenon restricted to chronic infections, but is also a
frequent outcome of acute infections [29]. Working with a P.
aeruginosa MRS-deficient strain in vitro, we previously established an
association between hypermutability and both mucoid conversion
[30] and lasR inactivation [31,32], both hallmarks of P. aeruginosa
infections in the CF airways. Similarly, Waine et al. [23] observed
an association between the hypermutator and the mucoid
phenotypes by examining P. aeruginosa isolates from adult CF
patients with chronic lung infections. Nevertheless, the role of
hypermutability in P. aeruginosa phenotypic diversification in the
natural scenario of a human infection has only very recently been
investigated by Mena et al. [22], who recently showed that this
genetic adaptation is catalyzed by hypermutators. However, the
hypermutability was not linked to any particular adaptive trait
(including genes involved in the antimicrobial resistance and lasR,
the latter of which showed a higher number of mutations). Hence,
these results show that the involvement of hypermutability in the
acquisition of the mutations which drive the adaptive process of P.
aeruginosa into the CF airways is complex. Also, exactly how P.
aeruginosa acquires those mutations which enable it to persist into
the CF lung environment is still an open question. These issues
need to be resolved in order to shed light on the mutational
mechanisms involved in P. aeruginosa adaptation.
In the present work, we carried out an exhaustive survey and
characterization of mutations in mucA (mucoid phenotype), lasR
(quorum sensing deficient phenotype), mexZ (multi-drug resistant
phenotype) and the MRS genes (hypermutator phenotype) in a
collection of P. aeruginosa isolates obtained from Argentinean CF
patients. mexZ turned out to be the most frequently mutated gene
followed by mucA and lasR, but mutations in all these three genes
were highly prevalent in our collection. Also, the occurrence of
hypermutators among Argentinean CF patients was very high,
with hypermutability being a consequence of mutations affecting
the MRS genes (mostly the mutL gene, but also mutS). However, the
mutational spectra of each gene were clearly different, suggesting
that more than one mechanism could be involved in the
mutational process of each gene. Our results show a lack of
association between hypermutability and the frequency of adaptive
mutations occurring in mucA, lasR and mexZ, and, although
hypermutability was associated with an increased resistance to
most of the antibiotics tested on P. aeruginosa isolates from the
Argentinean CF population, this association was not observed for
mucoid variants, quorum sensing deficiency or the mexZ related
multi-drug resistant phenotype.
This is the first detailed characterization of P. aeruginosa CF
isolates in Latin America which is focused on mucoidy, lasR-
deficiency, hypermutability and antibiotic resistance, critical issues
regarding CF chronic infections, and provides new insights into
the mutational mechanisms required for bacterial persistence.
Results
Phenotypic and genotypic characterization of the P.
aeruginosa isolates
Thirty-eight P. aeruginosa isolates were collected from the sputum
of twenty-six CF patients during the course of chronic pulmonary
infection (see Material and Methods). The samples were obtained
from child/teenage patients (18 isolates, 12 patients) as well as
from adult patients (20 isolates, 14 patients) obtained at two
Hospitals located in different Argentinean cities. In order to avoid
duplications, two isolates from the same patient were considered
different if they fulfilled at least one of the following conditions: 1)
they were isolated with a separation period of at least one year; 2)
they were obtained on the same date, but showed different colony
morphotypes (see Material and Methods).
We characterized all P. aeruginosa isolates based on their
mucoidy, iridescence at white light exposure, pigmentation, and
colony size. As shown in Table 1, this first phenotypic
characterization displayed the typical colony variant diversification
described for pulmonary chronic infection isolates, which differed
from the monomorphic variants isolated from P. aeruginosa acute
infections [5,6].
In order to explore the extent of clonality and the epidemiology
of the P. aeruginosa collection, we carried out a PFGE analysis of the
38 CF isolates. Each patient carried a single unique genotype that
persisted over time, even for those isolates that were obtained from
the same patient over several years (patients 3 and 18). Moreover,
the strains from different patients were epidemiologically unrelated
(Table 1), indicating that the infection in each patient was
established independently by bacterial lineages from different
environmental reservoirs.
Exceptions to this distribution were the isolates from patients 1
and 2, which demonstrated a closely related PFGE pattern
(Table 1). This exceptional case may indicate a very low
prevalence (5%) of transmission among patients in the Argenti-
nean population.
P. aeruginosa hypermutator strains in the Argentinean CF
population
In order to establish the prevalence of hypermutator strains in
the Argentinean P. aeruginosa CF isolates, we determined the
frequency of mutation to rifampin resistance for the 38 isolates.
Although this assay only allows the detection of base substitutions
in the rpoB gene [33], it is widely used as an efficient method to
detect MRS deficient strains [19,34].
Thus, the results were compared with those obtained for the
PAO1 reference strain (2.4610
2861.3610
28) as well as with
those from the MPAOMS (2.8610
2661.6610
26) and MPAOML
(1.3610
2660.6610
26) hypermutator mutant strains. In this sense,
clinical isolates were considered hypermutators when their
mutation frequencies were $2610
27, with this being an arbitrary
value which has been previously established to be reached/
surpassed mostly by MRS-defficient strains [19]. As observed in
Table 1, 16 hypermutators were identified among the 38 P.
aeruginosa isolates (42%), with these hypermutable P. aeruginosa
strains being obtained from 12 patients (46%). It is important to
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was very high in the adult population as well as in the child/
teenaged population.
Molecular characterization of the hypermutator strains
It has been described that the stable hypermutators found
among P. aeruginosa CF isolates are commonly deficient in the
Table 1. Genotypic and morphotypic characterization of the 38 P. aeruginosa CF isolates.
Patient Isolate Genotype
a Phenotype Source
Year of
isolation
Mucoidity SCV Pigmentation Iridescence Mutation Frequency
b
1a N D + -- - (1.360.7)610
25 HNC 2004
bA 1 + -- - (1.660.7)610
25 HNC 2007
cA 1 ++ - - (2.761.9)610
29 HNC 2007
2a A 1 - + - + (1.060.4)610
25 HNC 2007
bA 2 + -- - ( 1 . 7 61.4)610
29 HNC 2007
3a B 1 + -- - (1.060.7)610
25 HNC 2004
bB 1 - + -- (1.660.3)610
26 HNC 2007
cB 1 + - + (green) - (2.861.6)610
27 HNC 2008
4a C 1 + -- - ( 2 . 8 61.4)610
28 HNC 2007
bC 1 - - - - ( 9 . 0 66.3)610
29 HNC 2007
5a D 1 + -- - (4.562.6)610
26 HNC 2007
6 a E1 - - - - (6.464.5)610
29 HNC 2007
7a Q 1 - - + (green) - (2.960.8)610
28 HNC 2007
8a R 1 + -- - ( 2 . 2 60.5)610
28 HNC 2007
9a F 1 + -- - (3.560.3)610
26 HNC 2004
10 a L1 ++ -- (6.563.8)610
26 HNC 2008
11 a N1 + -- - ( 1 . 0 60.5)610
29 HNC 2008
12 a O1 + -- - ( 3 . 9 62.1)610
29 HCN 2008
13 a G1 - - - + (4.160.3)610
29 HABA 2006
14 a H1 - - + (green) - (5.063.2)610
29 HABA 2006
15 a S1 - ++ (red) - (1.160.6)610
27c HABA 2006
16 a I1 + - + (green) - (6.761.8)610
29 HABA 2006
17 a J1 - - + (green) - (2.661.5)610
29 HABA 2006
bJ 1 + -- - (6.062.8)610
26 HABA 2006
18 a K1 ++ - - (5.562.1)610
29 HABA 2006
bK 1 - + - - (2.962.3)610
28 HABA 2006
cK 1 + -- - ( 1 . 2 61.1)610
29 HABA 2008
dK 1 - + - + (1.361.2)610
26 HABA 2008
19 a M1 + -- - (2.660.4)610
26 HABA 2006
20 a P1 + - + (green) - (9.064.0)610
210 HABA 2008
bP 1 - - + (green) - (2.261.6)610
26 HABA 2008
21 a T1 ++ -- (1.560.3)610
26 HABA 2008
bT 1 - + - + (1.160.9)610
26 HABA 2008
22 a U1 + -- - (3.762.2)610
26 HABA 2008
23 a V1 - - + (green) - (1.961.3)610
29 HABA 2008
24 a W1 - - - + (4.062.0)610
210 HABA 2008
25 a X1 - - - + (1.160.2)610
27c HABA 2008
26 a Y1 + -- - ( 2 . 3 61.7)610
29 HABA 2008
aAll isolates were genotyped by PFGE using the SpeI enzyme.
bMutation frequency was measured as the occurrence of spontaneous resistance to rifampin 100 mg/ml.
cIsolates 15a and 25a with mutation frequencies nearly under the breakpoint ($2610
27) were discarded to be mutS or mutL deficient strains by gene sequencing (see
Table 2).
SCV, Small Colony Variant; ND, not determined; HNC, Hospital de Nin ˜os de Co ´rdoba; HABA, Hospital Alema ´n de Buenos Aires.
Those isolates with mutation frequencies $2610
27 were defined as hypermutators and indicated by bold type.
Mutation frequencies for PAO1 reference strain and MPAOMS and MPAOML hypermutator strains were (2.461.3)610
28, (2.861.6)610
26 and (1.360.6)610
26
respectively.
doi:10.1371/journal.pone.0012669.t001
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explored the genetic bases for the hypermutability of the 16 P.
aeruginosa hypermutator isolates by carrying out gene complemen-
tation assays as well as sequencing of the mutS and mutL genes. As
shown in Table 2, 15 hypermutator isolates (94%) were confirmed
to be defective in the MRS, of which 6 isolates showed a loss of
function in the mutS gene, and 9 in the mutL. This observation
differs from previous studies in which mutS was shown to be the
main target for the acquisition of a stable hypermutable state
[18,20]. For the remaining hypermutator isolate (3c), although
genetic complementation was not achieved due to this isolate
showing a natural resistance to gentamicin (not shown), a region of
its mutS gene could not be amplified by PCR, suggesting that this
strain could also be another mutS-deficient isolate. Mainly
Table 2. Mutations in the mucA, lasR and mexZ genes of the 38 P. aeruginosa CF isolates.
Isolate mucA lasR mexZ MRS genes
1a CRT at 349 (TAA at 349) ARG at 587 (E196G) CRG at 151 (H51D) mutS, 11 bp del at 1555 (TAA at 1854);
ARG at 1276 (T426A)
1b CRT at 349 (TAA at 349) ARG at 587 (E196G) CRG at 151 (H51D) mutS, 11 bp del at 1555 (TAA at 1854);
ARG at 1276 (T426A)
1c 1 bp del at 426 (TGA at 440) NF 1 bp del at 261 (TAA at 332) ND
2a NF 1 bp del at 308 (TGA at 341) 1 bp del at 242 (TAA at 332) mutL,T RA at 1874 (L625Q)
2b 1 bp del at 426 (TGA at 440) NF 1 bp del at 261 (TAA at 332) ND
3a 1 bp del at 426 (TGA at 440) NF NF mutL, 2 bp ins at 619 (TGA at 784)
3b 1 bp del at 426 (TGA at 440) NF NF mutL, 11 bp del at 619 (TGA at 782)
3c NF NF NF mutS,N A
4a 1 bp del at 426 (TGA at 440) NF 10 bp del at 595 ND
4b 1 bp del at 426 (TGA at 440) NF 10 bp del at 595 ND
5a 1 bp del at 426 (TGA at 440) NF NF mutS,A RC at 1477 (T493P)
6a NF NF 2 bp del at 60 ND
7a 1 bp del at 426 (TGA at 440) ARG at 626 (N209S) TRC at 110 (L37P) ND
8a CRT at 352 (TAG at 352) NF 10 bp del at 184 ND
9a CRT at 349 (TAA at 349) 2 bp del at 602 (TAG at 617) 14 bp del at 340 mutL, 17 bp del at 1240 and
GRT at 1632 (TGA at 1632)
10a CRT at 340 (TAG at 340) NF 11 bp del at 328 mutS,G RA at 1852 (G618S)
11a 1 bp del at 426 (TGA at 440) NF 1 bp deletion at 609 ND
12a NF NF NF ND
13a NF NA ARG at 633 (TAG 211 W) ND
14a NF NF ARG at 34 (T12A); GRA at 44 (G15D) ND
15a NF NF NA NF
16a 1 bp del at 201 (TGA at 284) NF 11 bp del at 365 ND
17a NF NF 38 bp del at 417 ND
17b NF NF 13 bp del at 340 mutS, 2 bp ins at 1611 (TGA at 1687);
TRC at 986 (L329P)
18a 1 bp del at 339 (TGA at 386) NF 4 bp del at 595 ND
18b 1 bp del at 339 (TGA at 386) NF 4 bp del at 595 ND
18c 1 bp del at 430 (TGA at 440) NF 15 bp del at 60 (DRVFLE at 22) ND
18d GRT at 421 (TAG at 421) CRT at 617 (A206V) NF mutS,1b pd e la t1 1 7 1( T G Aa t1 2 5 0 )
19a 1 bp del at 426 (TGA at 440) NF 368 bp del at 248 mutL, 5 bp ins at 627 (TGA at 782)
20a CRT at 367 (TAG at 367) TRG at 645 (I215M) CRT at 187 (C63R) ND
20b NF TRG at 645 (I215M) CRT at 187 (C63R); CRT at 283 (TAG at 283) mutL, 96 bp dup at 75 (TGA at 378)
21a NF CRT at 221 (P74L) 21 bp del at 631 mutL, 4 bp del at 1475
21b NF CRT at 221 (P74L) 21 bp del at 631 mutL, 4 bp del at 1475
22a 1 bp del at 358 (TGA at 386) CRT at 280 (TAG at 280) 12 bp del at 425 (DRAVE at 143; R142Q) mutL,C RT at 1474 (TGA at 1474)
23a GRC at 304 (G102R) ARG at 575 (K192R) TRGa t4 1 3a n dC RA at 414 (L150R); 7 bp del
at 451
ND
24a NF CRA at 317 (TGA at 315) CRA at 494 (TAG at 493) ND
25a NF ART at 697 (N233Y) NF NF
26a 1 bp del at 201 (TGA at 284) NF 12 bp del at 383 (DPLEK at 128) ND
NF, no mutation found; ND, not determined; NA, not PCR amplified; del, deletion; ins, insertion; dup, duplication.
doi:10.1371/journal.pone.0012669.t002
Adaptive Mutagenesis in CF
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12669frameshift mutations (62.5%, see below) were responsible for the
hypermutator phenotype in both the mutS and mutL genes,
including deletions and insertions (Table 2). Furthermore, in three
hypermutator isolates, missense mutations accounted for the
inactivation of the MRS genes: isolate 5a had a single point
mutation leading to a change in amino acid 493 from tyrosine to
proline (T493P), located in the clamp domain IV of the MutS
protein; isolate 10a contained a non-synonymous mutation in
mutS, G618S, one of the ADP-contacting residues of ATPase
domain V [35] that is highly conserved in all ABC ATPases
inhibited by vanadate [36]; and the remaining isolate 2a had a
single point mutation in mutL, which produced a change in amino
acid 625 from leucine to glutamine (L625Q). This amino acid is
one of the last 10 C-terminal residues that abolishe MutL
homodimerization upon deletion, a phenomenon that has a key
function in communicating mismatch recognition by MutS to
downstream repair processes. To our knowledge, these three
missense mutations have not been previously reported.
Finally, it is interesting to highlight the results obtained for
patients 1 and 3. From patient 1, we isolated a previous
hypermutator strain in 2004 (1a) and a subsequent hypermutator
strain in 2007 (1b) (Table 1). Both these isolates contained the
same 11 bp deletion in MutS and an identical single point
mutation (T426A), suggesting that the same hypermutator lineage
was maintained over three years of chronic infection. On the other
hand, the hypermutator isolates from patient 3 obtained in 2004
(3a) and 2007 (3b) harbored two different frameshifts, produced by
11 bp and 2 bp deletions inactivating mutL, respectively. In
addition, a third hypermutator isolate (3c) was obtained from
the same patient in 2008, which possessed an unaltered mutL
sequence but which failed to amplify a region of the mutS gene.
This result indicates that during four years of chronic infection in
patient 3, three different hypermutator lineages emerged,
suggesting a strong selection for hypermutability in the CF lung.
Screening of mutations in the mucA, lasR and mexZ
genes
The coding sequences of the mucA, lasR and mexZ genes were
analyzed in our collection of isolates to score for mutations that
could be involved in the phenotypic switches to mucoidy,
deficiency in the quorum sensing and antimicrobial (aminoglyco-
side) resistance respectively, three phenotypes considered to be
characteristics of P.aeruginosa chronic CF infections. Thus, only
nonsynonymous mutations which are expected to cause partial or
complete loss of function in these genes were considered in the
analysis (see Material and Methods).
As shown in Table 2, mexZ was the most frequently mutated
gene in our collection of isolates, with 30 out of 38 isolates
harboring mutations in this gene (79%). This was followed by
mucA, which showed mutations in 24 of the 38 isolates (63%), and
finally lasR, which was mutated in 15 isolates (39%). Taken
together, these results and the data from the MRS gene mutational
inactivation (42%) confirm that the occurrence of mutations in all
the analyzed genes was highly prevalent among Argentinean CF
patients.
Mutational spectra are remarkably different among
mucA, lasR, mexZ and MRS genes
Next we examined the mutational spectrum produced in each
gene. Interestingly, these mutational spectra presented large
differences among mucA, lasR, mexZ, and mutS/mutL, which were
particular to each gene (Figure 1). In mucA, small deletions
prevailed (64.7%) with the rest of the mutations consisting of
different kinds of transitions (25%) and transversions (8.3%)
(Figure 1A). Notably, both frameshift mutations and substitutions
generated premature stop codons in 92% of the cases (Table 2),
indicating the particular way in which mucA was mutated. In lasR,
missense substitutions prevailed (86%), with a 2:1 ratio for
transitions (57%) over transversions (29%) (Figure 1B), which
mainly produced changes in the amino acid sequences (Table 2).
In contrast with mucA, only 14% of mutations in lasR were small
deletions (Figure 1B). mexZ, on the other hand, showed mostly
deletions (65%), of which there was a high prevalence of large
deletions (.4 bp) (50%) respect to small deletions (1–4 bp) (15%),
followed by transitions (20%) and transversions (15%) (Figure 1C).
However, in mexZ, almost 15% of mutations generated premature
stop codons (Table 2). As mentioned above, mostly frameshift
mutations (62.5%) were responsible for mutS and mutL inactivation
(Table 2), including mainly large (31.5%) but also small deletions
(5.3%), small insertions (10.5%) large insertions (5.3%) and
duplications (5.3%), thus showing a wider mutational spectrum
(Figure 1D).
By comparing the mutational spectra obtained in the Argen-
tinean isolates with those reported in other studies [6,22,37–39],
we observed that our results coincided with those previously
described for mucA, lasR, mexZ and MRS, indicating that each gene
has a particular way of being mutated. Taken together, these
observations suggest that different mechanisms of mutagenesis are
responsible for the loss-of-function mutations in the analyzed
genes.
Mutations in the mucA, lasR and mexZ genes are not
linked to hypermutability in the Argentinean CF
population
Theoretical studies suggest that, under stressful conditions,
selective pressure favors hypermutator strains over nonmutator
strains [40–42]. In the particular case of P. aeruginosa chronic lung
Figure 1. Mutational spectra of mucA, lasR, mexZ and MRS genes observed in P. aeruginosa isolates obtained from Argentinean CF
patients. Pie charts indicate the observed percentage for each kind of mutation respect to the total number of mutations occurring in (A) mucA, (B)
lasR, (C) mexZ and (D) MRS genes. The analyses on MRS genes include mutations observed in mutS and mutL.
doi:10.1371/journal.pone.0012669.g001
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hypermutators in the population infecting an individual patient
may be sustained by their association (hitchhike) with mutations
adaptive to growth in the lung [19,20]. Related to this, in two
previous recent works, we showed in vitro that the MRS loss-of-
function was a key determinant in targeting mucA for mucoid
conversion and lasR for quorum sensing deficiency [30–32].
In order to investigate if an association could be established
between hypermutability and the mutations observed in the mucA,
lasR and mexZ genes in the Argentinean CF isolate collection, we
analyzed the proportion of mutations that occurred in each gene
in the hypermutator and nonmutator isolates. As shown in
Figure 2, we observed that in the hypermutator isolates, the
proportion of mutations that occurred in the mexZ and mucA genes
was not significantly different to that observed in the nonmutator
isolates (P=0.17 and P=1.00 respectively). In the case of lasR,w e
saw that among the hypermutators, the number of mutations per
isolate was higher (0.56) than nonmutators (0.27), although this
difference was not statistically significant (P=0.09), indicating that,
as in the case of mexZ and mucA, it was not possible to establish an
association between the occurrence of mutations in lasR and the
hypermutator phenotype. Furthermore, as shown in Figure 2, the
number of mutations per hypermutator isolate (2.06) was not
higher than that observed per nonmutator isolate (1.90).
We now investigated if hypermutability could be associated with
any particular kind of mutations in mucA, lasR and mexZ genes. It
was observed that although the hypermutator isolates showed a
tendency towards substitutions (53%), which were either transver-
sions or transitions, with nonmutator isolates displaying a higher
number of deletions (62%) (mainly small deletions between 1 to
4 bp), there was not a statistically significant difference between
hypermutators and nonmutators with respect to the kind of
mutations occurring in the analyzed genes. Furthermore, whatever
the type of mutations, their distribution among any particular
analyzed gene in hypermutators and nonmutators isolates did not
show any statistically significant differences (Figure 2). Therefore,
it was not possible to establish any association between
hypermutability and the nature of the mutations that occurred
in mucA, lasR and mexZ during the process of chronic lung
infection, suggesting that in the population analyzed in this work,
hypermutation was not linked (hitchhiked) to any of the specific
adaptive traits studied.
Hypermutability is associated to antimicrobial resistance
mainly through the presence of resistant mutant
subpopulations (RMS)
As mentioned above, several reports have established a link
between antimicrobial resistance and the occurrence of hypermu-
tators. In fact, it has been observed that hypermutator P. aeruginosa
strains isolated from CF patients not only possess a substantially
higher antibiotic resistance than nonmutator isolates [19], but also
increase the rate of acquisition of new antibiotic resistance [25].
Thus,inordertoinvestigatetheassociationbetweenhypermutability
and antibiotic resistance in the Argentinean P. aeruginosa CF isolates,
we tested the 38 isolates by measuring the inhibition zone diameters
and scoring for RMS within the inhibition zones of five different
antimicrobial agents (ceftazidime, ciprofloxacin, imipenem, mer-
openem and tobramycin). As shown in Table 3, the proportion of
hypermutator strains of P. aeruginosa with detectable levels of
ciprofloxacin and ceftazidime resistance was significantly higher
than the proportion observed in non-mutator strains (P=0.02and
P=0.02 respectively), indicating that in the Argentinean CF
population, hypermutability correlated with ciprofloxacin and
ceftazidime resistance. In fact, 62.5% of the hypermutators were
ciprofloxacin resistant compared to a proportion of 22.7% found
among nonmutators. Although a smaller proportion of hypermuta-
tors (25%) were ceftazidime resistant, all nonmutator strains were
susceptible to this antibiotic (Table 3). The prevalence of antibiotic
resistant strains for hypermutator and nonmutator isolates for
imipenem, meropenem, and tobramycin was biased towards the
hypermutators, although this was not statistically significant
(P=0.06, P=1.00 and P=0.61 respectively). Nevertheless, it is
important to point out that only one isolate (isolate 19a) that was a
hypermutatorshowedresistancetoalltheantibioticstested(Table3).
By quantifying the emergence of the resistant mutant subpop-
ulation (RMS) [43], we observed that most of the hypermutator
isolates showed RMS within the inhibition zones of the five
antibiotics tested. In contrast, RMS was rarely detected when the
nonmutator strains were tested for the same antibiotics. In fact,
every hypermutator isolate of this study showed RMS for at least
three different antibiotics, with the proportion of hypermutator P.
aeruginosa strains that showed RMS being significantly higher than
the non-mutator strains (P,0.001) (Table 3). These observations
are in agreement with a previous study, in which the disk diffusion
test was proposed as a reliable method for detecting hypermutator
strains from clinical isolates [43].
Finally, it is important to remark that in the Argentinean
population, the disk diffusion tests showed similar results for the
child/teenage and the adult groups of CF patients.
Antimicrobial resistance is not linked to mucoidy, lasR
inactivation or mexZ related multi-drug resistant
phenotype
Previous studies have reported an enhanced resistance to
antibiotics for mucoid strains of P. aeruginosa isolated from sputa
of CF patients [44]. Also, it has been proposed that mexZ
inactivation is involved in the development of stable aminoglyco-
side resistance among CF strains of P. aeruginosa [15]. An increased
tolerance to b-lactam has been attributed to inactivation of lasR,
which was not sufficient to alter the MIC, but resulted in a greater
production of spontaneous resistant colonies [9]. Moreover, it has
been recently observed that lasR loss-of-function mutations
confered resistance to ciprofloxacin and tobramycin when oxygen
Figure 2. Distribution of the number of mutations among
mucA, lasR and mexZ genes in hypermutator and nonmutator
isolates. The number of mutations occurring in mucA (blue bars), lasR
(green bars) and mexZ (red bars) is expressed as a percentage respect to
the total number of mutations found in hypermutator and nonmutator
isolates. Above the bars, the total number of mutations per isolate for
the hypermutator and nonmutator subpopulations is indicated.
doi:10.1371/journal.pone.0012669.g002
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Related to this, we investigated if the inactivation of mucA, lasR or
mexZ could be associated with an altered antibiotic resistance in
our collection. As shown in Figure 3, antibiotic resistance to b-
lactams ceftazidime, imipenem and meropenem, as well as
flouroquinolone ciprofloxacin and aminoglycoside tobramycin
was not associated with the mutagenic inactivation of mucA, lasR
or mexZ. Moreover, scoring for RMS within the inhibition zones of
the five antimicrobial agents tested showed that the presence of
resistant mutants was not a phenomenon related to the
inactivation of any of these three regulators, not even when the
lasR mutants were tested for b-lactam antibiotics (not shown).
Table 3. Antibiotic disk diffusion test and quantification of the resistant mutant subpopulations of the 38 P. aeruginosa CF
isolates.
Isolate MRS genes
a Ceftazidime Ciprofloxacin Imipenem Meropenem Tobramycin
DD RMS DD RMS DD RMS DD RMS DD RMS
1a - S +++ S ++ S +++ S +++ S ++
1b - S +++ I ++ S +++ S +++ R*
1c + S ++ S- S- S++ S-
2 a - R *R *S +++ S +++ S +++
2b + S + S- S- S+ S-
3a - I ++ I- S +++ S +++ I +++
3b - R * I ++ I +++ S +++ I +++
3c - S +++ S +++ S +++ S +++ S ++
4a + S- S- S- S- S-
4b + S- S- S- S- S-
5a - S - R * S ++ S +++ S +
6a + S- S- S- S- S-
7a + S- I - S- S- S-
8a + S- R* S+++ S +++ S-
9a - S ++ S +++ S +++ S +++ S +++
10a - S ++ S ++ S +++ S- S+++
11a + S- S- S- S- R*
12a + S- S- S- S- S-
13a + S- R* S- S- R*
14a + S- S- S- S- S-
15a + S- S- S- S- S-
16a + S- S- S- S- S-
17a + S - I- R * I- S -
1 7 b- S -S -I +++ S ++ S +
18a + S- S- S- S- S-
18b + S- R* S- S- S-
18c + S- S- S- S- S-
18d - S +++ R* R* S+++ R ++
1 9 a - R *R *R *R *R *
20a + S- S- S- S- S-
20b - S +++ R* R* S+++ S +++
21a - S +++ R* S++ S +++ S +++
21b - S +++ R* S+++ S +++ S +++
2 2 a - S -S -S ++ S +++ S +++
23a + S- S- S- S++ S-
24a + S- S- S- S- S-
25a + S- S- S- S- S-
26a + S- S- S- S- S-
aMRS genes was considered positive (+) when the sequences of mutS and mutL genes were wild type and negative (2) when were mutated.
DD, diffusion diameter zone; RMS, resistant mutant subpopulation: +,10 mutants; ++ 10 to 100 mutants; +++ .100 mutants.
Zone diameter interpretative criteria was according to CLSI: S, susceptible; I, intermediate resistance; R, resistant.
*lack of diffusion zone that prevents the resistant mutant subpopulation to be quantified.
doi:10.1371/journal.pone.0012669.t003
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P. aeruginosa establishes chronically in the CF airways by a
diversification process that allows fine tuning-adaptation and long-
term survival within the host. Since this process is mainly
mutagenic [6], a better understanding of the means by which P.
aeruginosa acquires these mutations may help to identify the
functions required for bacterial persistence.
In this study, we carried out a survey and a molecular
characterization of the mutations that occurred in the genes
which had been previously described as important determinants
for the adaptation of P. aeruginosa to the CF lung, due to their being
the most mutated among CF patients [6]. The mucA, lasR and mexZ
genes as well those implicated in the inactivation of MRS, mutS
and mutL, were analyzed in a collection of P. aeruginosa isolates
obtained from Argentinean CF patients, with this constituting the
first study of this nature in Latin America. According to our
results, mutations in the first three genes were highly prevalent in
the Argentinean population, with mexZ being the most frequently
mutated followed by mucA and lasR (Table 2). In addition, a high
prevalence of hypermutator strains was observed in our collection
(Table 1), in agreement with what has been previously reported in
other geographical regions [16–19]. All the hypermutator strains
were the result of a deficiency in MRS, and despite most reports
have described mutations in the mutS gene as the main cause of
hypermutability, followed by mutations in mutL and uvrD [18,20],
in our collection, mutations in mutL were actually the most
frequent cause of MRS deficiency, with the mutS gene alterations
playing a secondary role (Table 2). It is worth mentioning that,
based on the defined mutation frequency breakpoint ($2610
27),
our analysis was focused on strong MRS deficient hypermutators,
not considering weak mutators (usually with alterations in the
mutT, mutY and mutM genes of the GO system) which can also be
found among the CF P. aeruginosa isolates [16,19,46].
It is proposed that the high prevalence of stable hypermutator
strains of P. aeruginosa in the airways of CF patients is a
consequence of their second-order selection with other adaptive
mutations, since a higher mutation rate would increase their
probability to be acquired [42]. Related to this, an association
between hypermutability and mutations that confer antibiotic
resistance has been established by several reports [21,25,26,43,47].
Here, we also observed that MRS-deficiency was linked to
resistance to several antibiotics (Table 3), thus confirming that in
our collection, hypermutability was a key factor in the generation
of mutation-mediated resistance. However, antibiotic resistance
could not be associated to the mucoid phenotype [44] and the lasR
quorum sensing-deficient phenotype [9,15] (Figure 3). Even
inactivation of MexZ was not linked to antibiotic resistance in
our collection of isolates. This last observation results intriguing,
since inactivation of this gene leads to the overproduction of the
MexXY efflux system which is one of the most frequently reported
mechanisms of acquiring resistance to aminoglycoside and other
drugs among CF isolates [26] (Figure 3). Our results suggest that
antibiotic resistance due to overproduction of MexXY may require
the existence of additional regulatory mechanisms other than the
inactivation of mexZ [15,48,49]. Thus, it is possible to suggest that
those mutations linked to hypermutability, but not the inactivation
of mucA/lasR/mexZ, may confer a level of antibiotic resistance
detectable by disk diffusion, which is the methodology used in this
study.
In a previous recent work, we determined in vitro that MRS-
deficiency accelerates the acquisition of mucA [30] and lasR [31,32]
mutations, which led us to the hypothesis that such an association
may also be occurring in vivo. In line with this, Waine et al [23]
described a link between the hypermutator and mucoid pheno-
types in P. aeruginosa isolates obtained from CF patients. However,
in the present study, by scoring for mutations in hypermutator and
nonmutator CF isolates of our collection, no association could be
established between hypermutability and mutagenesis, not only for
mucA but also for the lasR and mexZ mutations. A possible
explanation for this discrepancy is that in Waine et al., the
phenomenon was not characterized at the genetic level, and that
the reversion phenomenon of the mucoid to a nonmucoid
phenotype, which is highly frequent in isolates recovered from
CF patients [38], was not evaluated. In fact, this analysis on our
collection showed that 37.5% of the non-mucoid isolates harbored
mutations in mucA, indicating that they had previously been
mucoid before reverting to the phenotype. Furthermore, contrary
to our isolates which were clonally different, almost half of the
isolates in Waine et al. corresponded to epidemic clones, a feature
that increases dissimilarities among collections.
It has been recently shown that hypermutator strains accelerate
the mutagenic genetic adaptation thus enhancing the accumula-
tion of new mutations [22]. However, no differences were
observed between hypermutators and nonmutators isolates with
respect to the distribution of mutations among several sequenced
Figure 3. Association between antibiotic resistance and inactivation of mucA, lasR and mexZ. (A) Differences in antibiotic resistance in the
P. aeruginosa isolates harboring mutations in mucA (mucA-) respect to those without mutations in mucA (mucA+). Data is expressed as the
percentage of resistant isolates to ceftazidime, ciprofloxacin, imipenem, meropenem and tobramycin in mucA- and mucA+ isolates. (B) The same
analysis was carried out in lasR- and lasR+ isolates and (C) mexZ- and mexZ+ isolates. In the three genes, the observed differences were not significant
(Fisher’s exact test) for any of the tested antibiotics.
doi:10.1371/journal.pone.0012669.g003
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on genes during the adaptation process in the lung, but was not
linked to any specific adaptive trait, even to antibiotic resistance.
[22]. Consistent with this antecedent, we observed similar
mutational spectra in the mucA, lasR and mexZ genes of
hypermutator and nonmutator isolates. However and most
interestingly, these mutational spectra vary in a gene dependant
manner, with mucA being dominated by small deletions (1 bp), lasR
by base substitutions and mexZ by large deletions (.4 bp). This
observation is intriguing, since it suggests the involvement of
different mechanisms of mutagenesis, possibly operating simulta-
neously, during the process of CF chronic infection. mucA and lasR,
but not mexZ mutational spectra coincide well not only with the
spectrum generated by a MRS deficiency [39,50] but also with the
activity of SOS-inducible error prone polymerases (i.e., Pol IV)
[51]. Therefore, it can be postulated that the induced hypermu-
tability due to the stressful milieu of the CF lung plays an
important role in mutagenesis, thereby contributing to the genetic
adaptation of P. aeruginosa to this environment. Consistent with this
hypothesis, we have recently shown that Pol IV activity is an
essential ingredient to establish mucA as the main target for
mutagenesis in mucoid conversion, with this factor having a
prominent role in the generation of -1 deletion in a monomeric
simple sequence repeats of five Gs (G
5-SSR426) one of the most
prevalent mutations among CF mucoid isolates [30]. In fact,
elimination of G
5SSR426 by site directed mutagenesis not only
significantly reduces the mutation frequency in mucA, but also
makes mucA to be no longer the major pathway for mucoid
conversion [52]. In a very recent work, carried out at the same time
as our study, a lack of association between stable hypermutability
and mucA and lasR mutations was also found [53]. According to this
work, mucoid isolates as well as lasR-deficient isolates occur prior to
the appearance of hypermutator strains, which had previously been
showntoaccumulateatlaterstagesofthe infection[6,47].Thus,itis
possible that mutations in these genes might be more important for
survival at the earlier stages of chronic infection, when the effect of
hypermutators is still poor. Taken all together, our results clearly
suggest that mutations which inactivate mucA, lasR and mexZ arise by
different mechanisms in each gene, with these being independent of
MRS-deficiency. However, further research is required to achieve a
better understanding of the complex and variable mutagenic
strategies used by P. aeruginosa to continuously adapt to the
environment of the CF lung.
Materials and Methods
P. aeruginosa isolates from CF patients
Thirty-eight P. aeruginosa isolates, representing different colony
morphotypes (with respect to mucoidy, iridescence, colony size
and pigmentation), were collected from sputum samples of 26
Argentinean CF patients with chronic P. aeruginosa lung infection
(with at least four years of continuous isolation of P. aeruginosa).
These patients were either children/teenagers or adults, who had
been treated at two local Hospitals: Hospital de Nin ˜os Santı ´sima
Trinidad (Co ´rdoba city) (12 patients; age range, 5 to 20 years;
mean age, 1363.5) or Hospital Alema ´n (Buenos Aires city) (14
patients; age range, 15 to 43 years; mean age, 2767). The P.
aeruginosa reference strain PAO1 and hypermutable strains
MPAOMS and MPAOML were used as controls (Table 4). All
strains were maintained and stored at 270uC in glycerol stocks.
For the different assays, strains were routinely subcultured on
Luria Bertani (LB) agar plates from the frozen glycerol stocks and
the inoculums were prepared using overnight cultures in LB broth
at 37uC with appropriate aeration.
Ethics Statement
The P. aeruginosa isolates were obtained from the Bacteriological
Laboratories of the Hospital de Nin ˜os Santı ´sima Trinidad
(Co ´rdoba) and Hospital Alema ´n (Buenos Aires), Argentina, as
byproducts of the routine established for bacterial typing and
antimicrobial susceptibility testing. In this sense, sputa sampling
was not performed with the aim to fulfill the study described in this
work, and isolates recovered from these sputa were just a
derivative of the habitual CF patient therapeutic controls. Thus,
we obtained a collection of 38 P.aeruginosa isolates which was
characterized in this work. It is important to clarify that bacterial
isolates were processed anonymously, there was no contact with
the patients or access to medical records, and that the therapeutic
treatments of the patients were not modified in any case as a
consequence of the results obtained in this study. The research
protocols followed in this study were approved and reviewed by
the Institutional Review Board of the Biological Chemistry
Research Center of Co ´rdoba (Centro de Investigaciones en
Quı ´mica Biolo ´gica de Co ´rdoba, CIQUIBIC), which waived the
need for a written consent from the patients involved.
Table 4. Bacterial strains, plasmids and primers used in this
study.
Genotype, relevant characteristics, or
sequence (59-39)
Source or
reference
Strains
P. aeruginosa
PAO1 wild-type; phototropic [60]
MPAOMS mutS::ISlacZA/hah (MPA32417); Tc
r [61]
MPAOML mutL::ISlacZA/hah (MPA46306); Tc
r [61]
Plasmids
pMC5-mutS pBBR1MCS-5 carrying P.aeruginosa mutS;G m
r [56]
pMC5-mutL pBBR1MCS-5 carrying P.aeruginosa mutL;G m
r [62]
Primers
mucA-for GAAGCCTGACACAGCGGCAAATGC
mucA-rev CCTCAGCGGTTTTCCAGGCTGGCTGC
lasR-for CACGGGCGCATGCGCCTC
lasR-rev AAGCTTCTATATAGAAGGGCA
mexZ-for CGCGACAGTAGCATATAATC
mexZ-rev TACATCGACGGCAAGCGCCT
mutS-for1 GCCCGTATGACCGACCTCT
mutS-rev1 CCGAGTCGCGATCGAAGT
mutS-for2 CCGCGCGCCATGGGACTTCGAT
mutS-rev2 TTCGGCGAGTTCGGGATA
mutS-for3 CACCACCATCGGCACCTAT
mutS-rev3 GTTGGCCACGAACGGTGT
mutS-for4 TGGTCGAGCAGGTGCTGG
mutS-rev4 ATTCTAGCAGCTTGTGCGG
mutL-for1 ACAGCCTGTCCAGCGACAAC
mutL-rev1 CTCGTCTCGCGCCTCGTGCA
mutL-for2 TGCACGAGGCGCGAGACGAG
mutL-rev2 TAACGGCGCGAAGTAGGCCTT
mutL-for3 AAGGCCTACTTCGCGCCGTTA
mutL-rev3 AGGCAGGGAAGACATCGGAAC
Tc
r, tetracycline resistance; Gm
r, gentamicin resistance.
doi:10.1371/journal.pone.0012669.t004
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All isolates were genotyped by PFGE using the SpeI enzyme as
described elsewhere [54]. The clonal relatedness was determined
according to Tenover et al. [55], who established that isolates with
PFGE patterns which differed: by 1–3 bands are closely related
clones; by 4–6 bands are possibly related clones; and by $7 bands
are considered to belong to different strains.
Determination of mutation frequency of P. aeruginosa CF
isolates
Mutation rates determined via fluctuation analysis can provide
good estimations of mutagenesis [53]. However, since our interest
was merely to identify hypermutators in the collection of P.
aeruginosa CF isolates, we performed the quantification of rifampin-
resistant mutant frequencies which is considered to be propor-
tional to the estimation of mutation frequencies. Mutation
frequencies were determined as previously described [56]. Briefly,
three bacterial colonies of each P. aeruginosa isolate were cultured in
LB medium at 37uC for 24 h with shaking performed at 225
r.p.m. Appropriate dilutions of the cultures were plated on LB
agar plates to determine the total number of viable cells, or on LB
agar supplemented with 100 mgm l
21 rifampin to count the
number of rifampin-resistant cells, following incubation overnight
at 37uC. Then, the mutation frequency was determined as the
ratio of the number of rifampin–resistant cells and the number of
viable cells. Strains were considered hypermutators when their
mutation frequencies were $2610
27, which corresponds to a
mutation frequency approximately 20 fold higher than that
obtained from the reference P. aeruginosa PAO1 strain
(2.461.3610
28) and which has been shown to score for strong
MRS-deficient mutators [19]. Determinations were carried out in
duplicate for two independent experiments, and the results were
expressed as means with their standard deviations.
Sequence analysis of mucA, lasR, mexZ, mutS and mutL
genes
Primers for PCR amplification and DNA sequencing of mucA,
lasR, mexZ, mutS and mutL genes are shown in Table 4. PCR
amplifications were performed under the following conditions:
8 min at 95uC, 33 cycles of 1 min at 94uC, 1 min 20 sec at 60uC
(for mucA, mexZ, mutS and mutL)o ra t5 0 uC( lasR) 2 min at 72uC,
and a final extension of 10 min at 72uC. The PCR products were
cleaned with a Gel Purification kit (QIAGEN) and both strands
were directly sequenced by using their respective PCR primers
(Macrogene Corp., USA). To score for mutations within the genes,
the sequencing results were compared with the corresponding
gene sequences of the PAO1 strain (www.pseudomonas.com) by
using the BLAST program of the NCBI database (www.ncbi.nlm.
nih.gov/blast/).
The analyses of the linkage between hypermutability and
mutations observed in mucA, lasR and mexZ included only
nonsynonymous mutations, which are expected to cause partial
or complete loss of function in the genes by generation of
premature stop codons, shifts of reading frames or deletions/
insertions in the coding sequence. To predict the effect of
nonsynonymous (missense) mutations on protein function, the
SIFT software was [57] used with default parameters (median
conservation of sequences=3; removal of sequences .90%
identical to the query). Mutations were considered as ‘‘not
tolerated’’ when P,0.05.
Complementation assays with the mutS and mutL genes
To investigate the genetic basis for the hypermutator pheno-
type, the hypermutator isolates were complemented with the
cloned P. aeruginosa wild-type mutS and mutL genes (Table 4).
Vector pBBR1MC-5 [58], which harbors mutS or mutL genes, was
successively transferred into the different hypermutator P.
aeruginosa CF isolates by electroporation as described by Choi
and Schweizer [59]. The transformants were selected on LB agar
plates supplemented with 100 mg of gentamicin ml
21, and the
complementation was checked by the rifampin test as described
above. For each isolate, complementation was verified for three
independent transformant colonies.
Antibiotic susceptibility tests and resistant mutant
subpopulation quantification
The inhibition-zone diameters of the thirty eight P. aeruginosa CF
isolates were determined for imipenem, meropenem, ceftazidime,
ciprofloxacin and tobramycin in Mueller-Hilton (MH) agar plates
by using conventional disks (Rosco). Approximately 0.5 McFar-
land standard suspensions were used for the inocula standardiza-
tion of each isolate, and the diameters of the inhibition zones were
measured after 24 h and 48 h of incubation at 37uC. The relative
number (,10, 10 to 100, .100) of resistant mutant subpopula-
tions growing within the inhibition zones was determined for each
antibiotic after 48 h of incubation at 37uC, as described previously
[43]. P. aeruginosa PAO1 strain and the hypermutable MPAOMS
and MPAOML strains (Table 4) were used as controls. All assays
were performed in duplicate.
Antibiotic multiresistance was defined as resistance to at least
three antibiotics.
Statistical analysis
Statistical analyses were performed using Fisher’s exact test,
considering a P value of .0.05 as significant.
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